查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
外陰陰道念珠菌病治療市場 - 全球行業規模、份額、趨勢、機會和預測，2018-2028 年，按藥物類別、給藥途徑、分銷渠道、按地區細分、競爭
市場調查報告書
商品編碼
1244139

外陰陰道念珠菌病治療市場 - 全球行業規模、份額、趨勢、機會和預測，2018-2028 年，按藥物類別、給藥途徑、分銷渠道、按地區細分、競爭

Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在預測期內，全球外陰陰道念珠菌病治療市場預計將出現顯著增長。

這是由於新型抗真菌藥物的不斷開發和全球醫療保健支出的增加。 此外，隨著老年人口的不斷增加，對低成本、同類最佳治療的需求不斷增長，世界各地區對外陰陰道念珠菌病藥物的需求正在顯著增加。 此外，全球癌症、心血管疾病、神經系統疾病和糖尿病等慢性病患病率的上升也將增加外陰念珠菌病治療的需求，並推動市場增長至 2028 年。預計 此外，在預測期內，人們對保持良好衛生意識的提高以及獲得新療法的廉價途徑的優勢預計將進一步支持外陰陰道念珠菌病治療市場。 此外，由於酵母菌感染導致氟康唑等廣譜抗生素的使用增加，預計將增加對外陰陰道念珠菌病藥物的需求並支持市場增長。 它是美國第二常見的陰道感染類型，僅次於細菌性陰道感染。 據估計，每年因陰道念珠菌病就診的門診人數約為 140 萬。

陰道念珠菌病流行率上升推動市場增長

由於急性外陰念珠菌病感染在人群中的流行率不斷上升，預計未來外陰念珠菌病市場將會增長。 此外，越來越多的研究檢查外陰念珠菌病和 RVVC 的流行也有望促進該部分的增長。 例如，根據《柳葉刀》雜誌發表的文章“傳染病分部：2018”，全球約有 1.38 億女性患有復發性外陰念珠菌病（急性外陰念珠菌病 12 個月內至少發作 3 次），每 10 萬人中有 3871 名女性患有每年來自外陰念珠菌病。 此外，慢性病在全球範圍內的擴散、對更好治療的需求不斷增長以及醫院獲得性感染的增加也推動了對外陰陰道念珠菌病藥物的需求。 此外，新興國家醫療保健支出的增加、肥胖和糖尿病患病率的上升、政府資金的增加以及政府和私人組織為傳播對該疾病及其預防措施的認識而採取的更多舉措都促進了外陰陰道念珠菌病的發展。它是擴大疾病治療市場的一個因素。

激活研發活動是市場發展的動力

在預測期內，外陰念珠菌病藥物和治療藥物研發的增加預計將促進全球外陰念珠菌病市場的增長。 2020 年 4 月，Scynexis Inc.宣布了一項令人鼓舞的第 3 期試驗結果，該試驗旨在確認抗真菌藥物 Ibrexafungerp 治療 VVC 的療效。 此外，主要的關鍵參與者已經向監管機構提交了治療陰道感染的藥物，這將使新藥的生產成為可能。 預計這些因素將在預測期內推動市場增長。 例如，2021 年 2 月，專注於開發藥物和藥物治療真菌感染的生物技術公司 SCYNEXIS, Inc. 與全球領先的合同商業化組織之一 Amplify Health 合作開發的 Brexafemme（Ibrexafungerp）在美國上市美國。

近期發展

2021 年 2 月，生物技術公司 Scynexis 和製藥公司 Amplify Health 擴大了對 Ibrexafungerp 品牌名稱 BrexafemmeTM 用於陰道感染的美國商業化的支持。宣布了一項協議。

2019年10月，美國製藥公司Mycovia Pharmaceuticals宣布將與匈牙利製藥公司Gedeon Richter合作生產外陰陰道念珠菌病治療藥物VT-1161。

競爭格局

公司概況：對全球外陰陰道念珠菌病治療市場主要參與者的深入分析。

可自定義：

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家）進行深入分析和概況分析。

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢概述

第 4 章 VOC（客戶之聲）

第5章臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成臨床試驗
  • 已完成臨床試驗
  • 管道細分（按開發階段）
  • 管道細分（按狀態
  • 管道細分（按研究類型）
  • 按地區劃分的渠道細分
  • 臨床試驗熱圖

第 6 章外陰陰道念珠菌病治療的全球市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按藥物類別（克黴唑、制黴菌素、氟康唑、酮康唑、特比□芬、特康唑等）
    • 按給藥途徑（口服、靜脈內、局部）
    • 按分銷渠道（醫院藥店、零售藥店、在線藥店）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 按治療類別
    • 按給藥途徑
    • 按分銷渠道
    • 按地區

第 7 章北美外陰陰道念珠菌病治療市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療類別
    • 按給藥途徑
    • 按分銷渠道
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 加拿大
    • 墨西哥

第八章歐洲外陰陰道念珠菌病藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療類別
    • 按給藥途徑
    • 按分銷渠道
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第九章亞太地區外陰陰道念珠菌病藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療類別
    • 按給藥途徑
    • 按分銷渠道
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第十章：南美外陰陰道念珠菌病藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療類別
    • 按給藥途徑
    • 按分銷渠道
    • 按國家
  • 南美洲：：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章中東和非洲外陰陰道念珠菌病藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療類別
    • 按給藥途徑
    • 按分銷渠道
    • 按國家
  • MEA：國家分析
    • 南非外陰陰道念珠菌病治療
    • 沙特阿拉伯外陰陰道念珠菌病治療
    • 阿聯酋外陰陰道念珠菌病治療

第 12 章市場動態

  • 司機
  • 任務

第13章市場趨勢與發展

  • 近期趨勢
  • 併購
  • 產品發布

第14章競爭格局

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Astellas Pharma Inc.
    • Mycovia Pharmaceuticals, Inc.
    • Basilea Pharmaceutica Ltd.
    • Scynexis, Inc.
    • Grupo Ferrer Internacional, S.A.
    • Pfizer, Inc.
    • Pacgen Life Science Corporation
    • NovaDigm Therapeutics, Inc.
    • Cidara Therapeutics, Inc.
    • Amplyx Pharmaceuticals Inc.

第15章 戰略建議

簡介目錄
Product Code: 14395

The Global Vulvovaginal Candidiasis Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing development of new antifungal drugs and growing healthcare expenditure across the globe. Additionally, the growing demand for the best treatment with a low cost, along with the growing geriatric population has significantly increased the demand for vulvovaginal candidiasis treatment across different parts of the globe. Additionally, the increasing prevalence of chronic diseases like cancer, cardiovascular diseases, neurological diseases, and diabetes across the globe is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby fuelling market growth through 2028. Besides, growing awareness of maintaining hygiene and the benefits of using new treatments with lower costs is further expected to support the vulvovaginal candidiasis treatment market during the forecast period. Furthermore, increasing usage of a broad-spectrum antibiotic such as Fluconazole because of yeast infection is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby supporting the market growth. It is the second most common type of vaginal infection after bacterial vaginal infections, in the United States. An estimated 1.4 million outpatient visits for vaginal candidiasis occur annually.

Growing Prevalence of Vaginal Candidiasis Is Driving the Market Growth

The growing prevalence of acute vulvovaginal candidiasis infection among the population is expected to grow in the vulvovaginal candidiasis market in the future. An increasing number of research to find the prevalence of the VVC or RVVC is also expected to boost segment growth. For instance, according to the article published in the Lancet Journal, Infectious diseases segment: 2018, globally, approximately 138 million women suffer from recurrent vulvovaginal candidiasis (relapse of acute vulvovaginal candidiasis, at least three times, within twelve months) and 3,871 per 100,000 women suffer from vulvovaginal candidiasis every year. Rapidly increasing chronic diseases across the globe, along with escalating demand for better treatment options and the increasing number of hospital-acquired infections, are also propelling the demand for vulvovaginal candidiasis treatment. Furthermore, growing healthcare expenditure in emerging countries, rising incidence of obesity and diabetes, growing government funding, and rising initiatives by government and private organizations to spread awareness about the disease and its preventive measures are the factors that will expand the vaginal candidiasis treatment market.

Rising Research & Development Activities Will Drive the Market's Growth

Increasing research and development on drugs and treatments for vulvovaginal candidiasis is predicted to boost the growth of the global vulvovaginal candidiasis market during the forecast period. In April 2020, Scynexis Inc. revealed the promising results of Phase III trials which were conducted to check the effectiveness of an anti-fungal drug, Ibrexafungerp for treating VVCs. Also, major key players are applying a new drug for treating vaginal infection to the regulatory bodies which will allow them to manufacture new drugs. These factors are expected to drive market growth in the forecast period. For instance, in February 2021, SCYNEXIS, Inc. a biotechnology company focused on developing therapies and drugs for fungal infections partnered with Amplify Health, one of the global leaders in contract commercialization organization, to launch Brexafemme (Ibrexafungerp) in the United States.

Market Segmentation

The global vulvovaginal candidiasis treatment market can be segmented by drug class, route of administration, distribution channel, and region. Based on drug class, the market can be segmented into Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Others. Based on the route of administration, the market can be differentiated into Oral, Intravenous, and Topical. Based on distribution channels, the market can be grouped into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global vulvovaginal candidiasis treatment market on account of the growing usage of broad-spectrum antibiotics for yeast infection in the country.

Recent Development

In February 2021, the biotech company, Scynexis announced its agreement with the pharmaceutical company, Amplify Health to extend its support for the U.S. commercialization of BrexafemmeTM which is a brand name of Ibrexafungerp for vaginal infections.

In October 2019, the American pharmaceutical company, Mycovia Pharmaceuticals announced its collaboration with the Hungarian pharmaceutical company, Gedeon Richter to manufacture VT-1161 for the treatment of vulvovaginal candidiasis.

Market Players

Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional, S.A., Pfizer, Inc., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc. are some of the leading players operating in the Global Vulvovaginal Candidiasis Treatment Market.

Report Scope:

In this report, global vulvovaginal candidiasis treatment market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvovaginal Candidiasis Treatment Market, By Drug Class:

  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others

Vulvovaginal Candidiasis Treatment Market, By Route of Administration:

  • Oral
  • Intravenous
  • Topical

Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Vulvovaginal Candidiasis Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Vulvovaginal Candidiasis Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Vulvovaginal Candidiasis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others)
    • 6.2.2. By Route of Administration (Oral, Intravenous, Topical)
    • 6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Drug Class
    • 6.3.2. By Route of Administration
    • 6.3.3. By Distribution Channel
    • 6.3.4. By Region

7. North America Vulvovaginal Candidiasis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Vulvovaginal Candidiasis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Vulvovaginal Candidiasis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Vulvovaginal Candidiasis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. Europe Vulvovaginal Candidiasis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Germany Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. United Kingdom Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Italy Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. India Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Japan Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. South Korea Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Australia Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By Distribution Channel

10. South America Vulvovaginal Candidiasis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Vulvovaginal Candidiasis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Argentina Vulvovaginal Candidiasis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Colombia Vulvovaginal Candidiasis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Vulvovaginal Candidiasis Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Vulvovaginal Candidiasis Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Vulvovaginal Candidiasis Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Astellas Pharma Inc.
    • 14.6.2. Mycovia Pharmaceuticals, Inc.
    • 14.6.3. Basilea Pharmaceutica Ltd.
    • 14.6.4. Scynexis, Inc.
    • 14.6.5. Grupo Ferrer Internacional, S.A.
    • 14.6.6. Pfizer, Inc.
    • 14.6.7. Pacgen Life Science Corporation
    • 14.6.8. NovaDigm Therapeutics, Inc.
    • 14.6.9. Cidara Therapeutics, Inc.
    • 14.6.10. Amplyx Pharmaceuticals Inc.

15. Strategic Recommendations